Thursday 16 October, 2025
Introduction: In recent years, antibody-based therapeutics have shown promise, particularly in cancer treatment. However, the high cost of laboratory experiments,…
Read moreAbstracts
Pharmacokinetic and Pharmacodynamic Modeling and Simulation Analysis of Nesuparib (JPI-547) in Patients with Advanced Solid Tumor
Thursday 16 October, 2025
Introduction: Nesuparib (JPI-547) is an anti-cancer agent under development that acts as a dual inhibitor of poly(ADP-ribose) polymerase and tankyrase….
Read morePopulation pharmacokinetic model of infliximab in patients with fistulising Crohn’s disease
Thursday 16 October, 2025
Introduction: Infliximab (IFX), anti-tumour necrosis factor alpha antibody, is widely used in the treatment of inflammatory bowel diseases. Patients with Crohn’s…
Read moreExternal evaluation of selected infliximab population pharmacokinetic models on patients with fistulizing Crohn’s disease
Thursday 16 October, 2025
Introduction: The development of fistulas in patients with Crohn’s disease is a recognised complication of this chronic disorder, posing challenges for…
Read morePK/PD of unfractionned heparin during cardiopulmonary bypass: an individual patient data meta-analysis of two studies
Thursday 16 October, 2025
Introduction: Unfractionated heparin (UFH) is commonly used during cardiac surgery under cardiopulmonary bypass (CPB) to prevent blood activation and thrombosis…
Read morePopulation pharmacokinetics of intravenous midazolam in critically ill patients supported with extracorporeal membrane oxygenation therapy
Thursday 16 October, 2025
Objectives: Extracorporeal membrane oxygenation (ECMO), allows the life-supporting treatment for patients who have severe cardiac or respiratory failure, and the instrument…
Read moreExplainable Machine Learning prediction of edema adverse events in NSCLC patients treated with tepotinib
Thursday 16 October, 2025
Objectives: Tepotinib is an ATP-competitive reversible inhibitor of the mesenchymal-epithelial transition factor (c-MET) receptor tyrosine kinase [1] currently approved for…
Read moreGenerative Models for Synthetic Data Generation: Application to PKPD data
Thursday 16 October, 2025
Objectives: The generation of synthetic (artificial) patient data that possess the statistical properties of the original ones plays a fundamental…
Read moreIndividualized tacrolimus dosing in pediatric kidney transplantation: development of PBPK-based predictive models, simulations and applications (ModSimTer-Tacro Study)
Thursday 16 October, 2025
Objectives: Development of individual dosage (ID) methods is a long-standing goal pursued by clinicians. Therapeutic individualization requires processing a significant…
Read moreInvestigating Interoccasion Variability and Estimation Methods
Thursday 16 October, 2025
Objectives: Interoccasion (IOV) variability, also known as the variability that accounts for the changes in individual pharmacokinetic (PK) parameters between…
Read more